Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company that regularly issues news and updates about its inflammation and immunology pipeline targeting the innate immune system. This news page aggregates company press releases and third-party coverage related to INmune Bio’s DN-TNF platform, CORDStrom™ mesenchymal stromal cell platform, and INKmune® natural killer cell priming platform.
Readers can find updates on XPro™ (XPro1595, pegipanermin), a selective soluble TNF neutralizer that the company is developing for neurological diseases driven by chronic inflammation. Recent news has highlighted Phase 2 MINDFuL trial results in early Alzheimer’s disease with inflammatory biomarkers, neuroimaging analyses using advanced MRI techniques, and manuscript submissions to peer-reviewed journals. The company also reports on scientific presentations at conferences such as the Clinical Trials on Alzheimer’s Disease (CTAD) meeting and the Alzheimer’s Association International Conference.
News related to the CORDStrom™ cell therapy platform includes clinical and manufacturing milestones in recessive dystrophic epidermolysis bullosa (RDEB), such as completion of a blinded randomized trial, pilot-scale commercial manufacturing runs at a cell and gene therapy manufacturing center in the United Kingdom, and intellectual property developments. INmune Bio also issues updates on participation in industry events and panels focused on dermatologic rare diseases and cell therapy manufacturing.
For the INKmune® platform, news items cover progress in the CaRe PC Phase I/II trial in metastatic castration-resistant prostate cancer, including reports that the trial met its primary and certain secondary endpoints, safety observations, and biomarker findings related to NK cell activation. Corporate news, including financing transactions, management changes, and special stockholder meetings, is also disclosed through regular press releases and corresponding SEC filings. Investors and researchers can use this page to follow INMB news on clinical data, regulatory plans, manufacturing scale-up, and corporate developments.
INmune Bio, Inc. (NASDAQ: INMB) recently presented at the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's diseases held from March 15-20 in Barcelona, Spain. The company emphasized the growing importance of targeting neuroinflammation in Alzheimer's Disease (AD) treatments, particularly with its Xpro™ therapy. Notable findings include improved synaptic function indicators post-treatment and the use of white matter pathology as a biomarker for predicting AD progression. CEO R.J. Tesi highlighted the significance of these insights in advancing clinical trials and drug development strategies.
INmune Bio (NASDAQ: INMB) presented nine data pieces at the AD/PD™ 2022 International Conference, held from March 15-20 in Barcelona, focusing on XPro™'s potential in treating Alzheimer’s Disease. This marks the first exposure for many EU and UK clinicians to INmune Bio’s approach targeting neuroinflammation. Key presentations include MRI measures from the Phase 1 trial and insights for Phase 2 trial design. The data emphasizes XPro™’s versatility and novel biomarkers being utilized in clinical strategies.
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company, announced that its CEO, RJ Tesi, MD, will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Dr. Tesi's corporate overview is scheduled for March 16, 2022, at 11:20am ET. Additionally, he will join a fireside chat at the 2022 Maxim Group Virtual Growth Conference on March 30, 2022, at 11:00am ET. INmune Bio is focused on treatments leveraging the immune system to combat diseases like cancer and Alzheimer's. Visit www.inmunebio.com for more information.
INmune Bio, Inc. (NASDAQ: INMB) announced positive results from ongoing clinical trials, including a Phase I trial using INKmuneTM for high-risk myelodysplastic syndrome (MDS) that showed a 60% activation rate of NK cells in a patient after therapy. The company also opened a Phase II trial for treating mild Alzheimer's disease (AD) with XProTM, expecting data in 2023. Financially, INMB reported a net loss of $30.3 million for 2021 but had cash reserves of approximately $74.8 million as of December 31, 2021. Upcoming milestones include expansion of clinical trial sites and additional patient enrollments.
INmune Bio (NASDAQ: INMB) will host a conference call on March 3, 2022, at 4:30 PM ET, to discuss its fourth-quarter results for 2021 and provide a corporate update. The call can be accessed via phone or through a live audio webcast. Participants are encouraged to join several minutes early. A transcript and a replay will be available shortly after the call. INmune Bio is focused on developing therapies that leverage the innate immune system to tackle diseases, with ongoing clinical trials involving products like INB03 and XPro.
INmune Bio, Inc. (NASDAQ: INMB) announced its President and CEO, Raymond J. Tesi, will present at the BIO CEO & Investor Conference in New York City from February 14-17, 2022. The presentation is scheduled for February 15 at 9:15 AM ET. Attendees can schedule virtual one-on-one meetings with the company during the conference. INmune Bio focuses on harnessing the innate immune system to develop treatments for diseases, with ongoing clinical trials for its product platforms, DN-TNF and NK Cell Priming.
INmune Bio (NASDAQ: INMB) has announced a pre-clinical research collaboration with the Chinese University of Hong Kong to evaluate its NK cell priming platform, INKmune™, in treating nasopharyngeal cancer (NPC). This partnership will leverage access to established NPC cancer cell lines. INMB's Chief Executive Officer, RJ Tesi, stated that this collaboration validates INKmune's versatility, targeting a cancer with high mortality rates and limited treatment options. The grant supports pre-clinical work, potentially leading to clinical trials in the UK, Hong Kong, and the US.
INmune Bio, a clinical-stage immunology company (NASDAQ: INMB), announced participation in upcoming investor conferences and a medical meeting. Key events include a panel discussion at LifeSci Advisors' 11th Annual Corporate Access Event on January 6, 2022, and a presentation at H.C. Wainwright Bioconnect Conference on January 10, 2022. Additionally, Professor Mark Lowdell will chair a session at the Allogeneic Cell Therapies Summit Europe on January 19, 2022. The company focuses on developing therapies that utilize the innate immune system to combat diseases such as cancer and Alzheimer’s.
INmune Bio (NASDAQ: INMB) presented data at the San Antonio Breast Cancer Symposium indicating that MUC4 expression is a key predictor of worse survival and treatment resistance in triple negative breast cancer (TNBC). The therapy INB03 can potentially reverse this resistance by reducing immunosuppression in the tumor microenvironment. Key findings show INB03 enhances macrophage phagocytosis and lymphocyte function, while decreasing TNBC's metastatic potential. The poster is presented by Dr. Roxana Schillaci on December 10, 2021, emphasizing the role of MUC4 in guiding combination therapies for improved patient outcomes.
INmune Bio, Inc. (NASDAQ: INMB) announced two poster presentations at the 2021 British Society of Immunology Congress. The presentations highlighted the mechanism of action of INKmune, demonstrating its ability to generate memory-like NK cells and promote their proliferation. Notably, a patient treated with INKmune showed a significant increase in NK cell activation post-treatment. The presentations could have important implications for cancer therapy, showcasing INKmune's potential in enhancing NK cell function against tumors.